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Plants are ideal for the production of protein-based nanomaterials because they
synthesize and assemble complex multimeric proteins that cannot be expressed
efficiently using other platforms. Plant viruses can be thought of as self-replicating
proteinaceous nanomaterials generally stable and easily produced in high titers. We
used Potato virus X (PVX), chimeric virus particles, and Cowpea mosaic virus, empty
virus-like particles to display a linear peptide (lipo) derived from human lipocalin, which is
immunodominant in Sjögren’s syndrome (SjS) and is thus recognized by autoantibodies
in SjS patient serum. These virus-derived nanoparticles were thus used to develop
a diagnostic assay for SjS based on a direct enzyme linked immunosorbent assay
format. We found that PVX-lipo formulations were more sensitive than the chemically
synthesized immunodominant peptide and equally specific when used to distinguish
between healthy individuals and SjS patients. Our novel assay therefore allows the
diagnosis of SjS using a simple, low-invasive serum test, contrasting with the invasive
labial biopsy required for current tests. Our results demonstrate that nanomaterials
based on plant viruses can be used as diagnostic reagents for SjS, and could also
be developed for the diagnosis of other diseases.
Keywords: molecular farming, Sjögren’s syndrome, diagnosis, ELISA, VPN, PVX, CVP, lipocalin
INTRODUCTION
Sjögren’s syndrome (SjS) is a complex chronic systemic autoimmune disease that may present
alone as primary SjS (pSjS) or associated with other autoimmune diseases as secondary SjS
(sSjS). The prevalence of pSjS in the general population is between 0.01 and 0.1% with a
higher incidence of the disease in women than in men (9:1; Maldini et al., 2013). The clinical
symptoms of pSjS include local exocrinopathy, resulting in dry eyes and mouth, extraglandular
and systemic manifestations such as arthralgias and fatigue, and severe systemic symptoms
such as vasculitis, pulmonary ﬁbrosis, glomerulonephritis and neurological pathology (Tzioufas
et al., 2012). The heterogeneity of pSjS often delays diagnosis (Patel and Shahane, 2014) and
many cases are overlooked due to the absence of sensitive and speciﬁc disease markers and
other deﬁnitive criteria for classiﬁcation (Plesivcnik Novljan et al., 2014; Rasmussen et al.,
2014).
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Current diagnostic criteria include the presence of antinuclear,
anti-Ro-SSA and/or anti-La-SSB antibodies, but antinuclear
antibodies are only detected in 60–85% of patients, anti-Ro-SSA
antibodies in 52–67% of patients and anti-La-SSB antibodies in
∼49% of patients (Nardi et al., 2006; Routsias and Tzioufas,
2007; Suresh et al., 2015). The American European Consensus
Group (AECG) criteria have been widely adopted and comprise
six key signs (Baldini et al., 2012): 1 – ocular symptoms, 2 –
oral symptoms, 3 – a positive Schirmer’s test, 4 – a positive
labial biopsy, 5 – salivary ﬂow symptoms, and 6 – the presence
of autoantibodies anti-SSA (Ro) or anti-SSB (La). At least three
of these signs should be present for a preliminary diagnosis
of pSjS. If four symptoms are present including 4 and/or 6,
or if three of symptoms 3, 4, 5, and 6 are present, then the
diagnosis is conﬁrmed. The anti-SSA (Ro) and anti-SSB (La)
autoantibodies listed among the AECG criteria are common in
other autoimmune diseases and therefore do not oﬀer a rigorous
pSjS diagnosis at an early stage when other symptoms are absent
(Shen et al., 2012). A labial biopsy is therefore mandatory for
conﬁrmation, and is the only indicative diagnosis in the absence
of autoantibodies and other symptoms (Patel and Shahane, 2014).
This has driven researchers to seek more reliable autoantigens
and autoantibodies suitable for early diagnosis.
The expansion of proteomics in medicine has led to the
discovery of speciﬁc immunodominant epitopes associated with
autoimmune diseases, resulting in novel immunoassays with
better predictive power. The most widely used immunoassays
are based on the enzyme linked immunosorbent assay (ELISA),
in which a passively adsorbed antigen is used to identify
samples containing reactive antibodies. This is a simple and
rapid technique which is routinely applied in many laboratories
(Engvall and Perlmann, 1972). ELISAs tend to be highly speciﬁc,
and where cross-reactivity results in a false-positive diagnosis,
this is usually less to do with multiple antibody types in
polyclonal sera and more to do with the conservation of epitopes
between target and non-target proteins. Whole proteins present
several epitopes that increase the likelihood of cross-reactions,
so the use of antigenic peptides comprising single epitopes
can remove this risk (Haist et al., 1992). For example, the
diagnostic peptide ELISA for Chagas disease has a sensitivity of
96.8–100% and a speciﬁcity of ∼99% (da Silveira et al., 2001).
Peptides are also advantageous because they can be usually
chemically synthesized whereas whole proteins must be produced
using recombinant DNA technology (Plesivcnik Novljan et al.,
2014).
One major drawback of peptide ELISAs is the ineﬃcient
binding of peptides to solid substrates such as microtiter plates
(Griesmann et al., 1991). Binding depends on the mass of
the peptide and its amino acid composition, and if much
of the peptide is involved in non-speciﬁc absorption then
the relevant epitopes can be obscured (Sallberg et al., 1995;
Gregorius et al., 1999; Gregorius and Theisen, 2001). Two
major strategies have been developed to stabilize the peptides
used in diagnostic ELISAs, one based on chemical modiﬁcation
and the other based on the use of biological nanoparticles
for peptide display. Whereas chemical modiﬁcation involves
the addition of functional groups that bind to polystyrene
(Gregorius and Theisen, 2001; Kumada et al., 2009), the
nanoparticle-based method involves the use of virus-derived
nanoparticles (VNPs) as scaﬀolds allowing the peptide to
be presented and accessed (Sanchez et al., 2013). Structural
evaluations should be carefully considered in the context of
VNPs conformation and peptide displaying region. Plants can
be used successfully to produce plant VNPs in large quantities.
These VNPs can be used to coat ELISA plates, resulting in a
substantial improvement in the detection of speciﬁc antibodies
in sera compared to peptide ELISAs (Sanchez et al., 2013).
VNPs displaying antigens have also been developed as vaccines,
imaging reagents and drug delivery vehicles (Lico et al., 2012).
Several plant viruses have been exploited for these purposes
including Cowpea mosaic virus (CPMV; Montague et al., 2011),
Tomato bushy stunt virus (Kumar et al., 2009), Tobacco mosaic
virus (McCormick and Palmer, 2008), Turnip mosaic virus
(Sanchez et al., 2013), and Potato virus X (PVX; Lico et al.,
2009).
Virus-derived nanoparticles displaying pSjS-associated
peptides have the potential to enhance the sensitivity and
speciﬁcity of autoantibody detection and therefore allow earlier
and more accurate diagnosis. Autoantibodies have been detected
against several candidate proteins in pSjS animal models,
including salivary gland protein-1 (SP1), carbonic anhydrase
6 (CA6), and parotid secretory protein (PSP), but these have
proven unsuitable for diagnosis in humans (Shen et al., 2014). In
contrast, lipocalin is selectively recognized by sera from human
pSjS patients and could therefore provide a suitable autoantigen
for diagnostic ELISAs (Johnsson et al., 2003; Navone et al., 2005).
Tear lipocalin is a protein belonging to the lipocalin family
and the calycin superfamily, which are a diverse set of proteins
that function as extracellular binding proteins. Lipocalins are
a family of low molecular weight proteins (18–40 kDa) with
prevalent extracellular functions. Speciﬁcally tear lipocalin is
highly expressed both in tears and saliva and it accounts for
about 15–33% of the protein tear and it is the major lipid
binding protein in human tear (Dartt, 2011). Together with
other protein of lipocalins family, tear lipocalin has been termed
immunocalins, related to their role in immunity. Particularly
tear lipocalins could have protective immunoregulatory, anti-
inﬂammatory, and antimicrobial eﬀects in the tears and ocular
surface and together with the other immunocalins seems
to act as part of the cytokine immune network and as a
key regulators of inﬂammatory cells, included natural killer,
neutrophils, monocytes, macrophages, B and T lymphocytes
and interfering with platelet aggregation and adherence of
neutrophils and monocytes to vascular endothelium (Gasymov
et al., 2005).
Given the reported relevance of lipocalin in SjS pathogenesis,
we produced VNPs based on CPMV and PVX displaying the
immunodominant lipo peptide from lipocalin (Navone et al.,
2005) and compared their sensitivity, speciﬁcity, reproducibility
and stability in diagnostic ELISAs compared to the ELISAs
based on the synthetic peptide. The use of PVX- and CPMV-
based systems, characterized by diﬀerent viral shapes and
peptide display context, allows to evaluate the inﬂuence of VNP
structures on ELISA performance.
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MATERIALS AND METHODS
Ethical Statement
A written informed consent was obtained from all the
participants in the study. The study was approved by the
local Ethical Committee (University of Verona) and all clinical
investigations have been conducted according to the principles
expressed in the Helsinki declaration.
Patients and Controls
Between January 2005 and December 2013, we obtained serum
samples from patients and healthy controls. Blood samples were
collected from the participants using a Vacutainer system (Becton
Dickinson, Franklin Lakes, NJ, USA) and were stored at –20◦C.
All the sera were tested for antibodies against nuclear antigens
(ANA), extractable nuclear antigens (ENA), and lipocalin by
ELISA. Blood samples were obtained after all the subjects
provided written informed consent.
We studied a cohort of 91 patients (5 males and 86 females, age
range 28–73 years) aﬀected by pSjS (Vitali et al., 2002), attending
the Unit of Autoimmune Diseases at the University Hospital of
Verona. A cohort of 60 patients aﬀected by rheumatoid arthritis
(RA), systemic sclerosis (SSc), and systemic lupus erythematosus
(SLE) was also studied as disease controls. RA patients met
the American College of Rheumatology classiﬁcation criteria
(Aletaha et al., 2010), the SSc patients met the American College
of Rheumatism/European League Against Rheumatism criteria
(van den Hoogen et al., 2013a,b) and the SLE patients met
the American College of Rheumatology and Systemic Lupus
International Collaborating Clinics criteria (Yu et al., 2014;
Amezcua-Guerra et al., 2015). All the patients were enrolled
consecutively regardless of disease activity and treatment, and
were assessed for clinical features and organ damage. A further
cohort of age/sex-matched healthy subjects served as a control
group.
Lipocalin Peptide Synthesis
The lipocalin synthetic peptide FEKAAGARGLST (lipo) was
designed based on the sequence of tear lipocalin as previously
described (Navone et al., 2005) and purchased with free
amino- and carboxy- terminal ends by Tib MolBiol (Genoa,
Italy). In particular, lipocalin peptide is part of the whole
protein corresponding to the sequence spanning from 148 to
159 aminoacids of the whole protein (UniProtKB/Swiss-Prot:
Q5VSP4.1). The purity of the peptide was 98%.
PVX Chimeric Virus Particles
Chimeric PVX particles displaying the lipocalin peptide (PVX-
lipo) were prepared using the pPVXSma vector and cloning
procedure as previously described (Lico et al., 2006). A sense and
antisense oligonucleotide pair was designed to amplify a product
with NheI and SmaI compatible ends in which the lipocalin
peptide sequence optimized for Nicotiana benthamiana codon
usage was preceded by an ATG codon and a serine residue (5′-
CTA GCC TCG AGA TGT CTT TTG AAA AGG CTG CTG
GTG CTA GAG GTT TGT CTA CTC-3′ and 5′-CCG GGA
GTA GAC AAA CCT CTA GCA CCA GCA GCC TTT TCA
AAA GAC ATC TCG AGG-3′). The ﬁnal expression vector
(pPVXSma-lipo) was used for the primary infection of 4–5-
week-old N. benthamiana plants, by abrading the surface of two
leaves with 20 μg of plasmid DNA and carborundum (VWR
International, Milan, Italy). The expression of the chimeric coat
protein (CP) gene and the genetic stability of viral genome after
several re-infection cycles (using sap from symptomatic leaves
in the previous infection cycle) were veriﬁed by RT-PCR (Lico
et al., 2006). The presence of PVX particles in infected leaf
protein extracts was conﬁrmed by western blot analysis. Brieﬂy,
plant tissue was ground to a ﬁne powder under liquid nitrogen
and homogenized in three volumes of phosphate buﬀered
saline (PBS) containing protease inhibitor cocktail (Sigma–
Aldrich, St Louis, MO, USA). After centrifugation (30,000 × g,
30 min, 4◦C), the supernatant was collected and the total
soluble protein (TSP) extracts were separated by 14% sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto a nitrocellulose blotting membrane (GE
Healthcare, Uppsala, Sweden). Themembrane was probed for 2 h
at room temperature using the alkaline phosphatase-conjugated
anti-PVX CP antibody (Agdia, Elkhart, IN, USA) diluted 1:200,
followed by detection using NBT/BCIP (Sigma–Aldrich, St Louis,
MO, USA).
For the large-scale puriﬁcation of PVX-lipo, approximately
50 g of symptomatic N. benthamiana leaves was processed as
previously described (Uhde et al., 2005). The purity of the
particles was veriﬁed by 14% SDS-PAGE and silver staining,
and the concentration was determined by measuring the
absorbance at 280 nm. N. benthamiana plants were also infected
with pPVX201 (Baulcombe et al., 1995) for the production
and puriﬁcation of unmodiﬁed PVX particles using the same
procedure.
CPMV Empty Virus Like Particles
Cowpea mosaic virus empty virus-like particles (eVLPs)
displaying the lipocalin peptide (CPMV-lipo) were produced
using the vectors pEAQ-HT-VP60 and pEAQ-HT-24K
(Saunders et al., 2009). A sense and antisense oligonucleotide
pair was designed to amplify a product with NheI and AatII
compatible ends (5′-CTA GCA CTC CTC CTG CTT TTG AAA
AGG CTG CTG GTG CTA GAG GTT TGT CTA CTC CAT
TTT CAG ACG T-3′ and 5′-CTG AAA ATG GAG TAG ACA
AAC CTC TAG CAC CAG CAG CCT TTT CAA AAG CAG
GAG GAG TG-3′) which was inserted into pEAQ-HT-VP60
digested with the same enzymes to yield pEAQ-HT-VP60-lipo.
Agrobacterium tumefaciens strain LBA4404 was transformed
with pEAQ-HT-VP60-lipo or separately with pEAQ-HT-24K by
electroporation, and bacterial cultures carrying each vector were
grown separately to the stable phase in Luria Broth (LB medium)
supplemented with the appropriate antibiotics. The cultures were
then centrifuged at 4000 × g and resuspended in MMA buﬀer
(10 mMMES pH 5.6, 10 mMMgCl2, 100 mM acetosyringone) to
an OD600 of 0.8. After incubation for 1–4 h at room temperature,
equal volumes of the two bacterial suspensions were mixed and
used for the syringe inﬁltration of 4–5-week-old N. benthamiana
leaves (four expanded leaves per plant). Inﬁltrated leaves were
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sampled 6 days post infection (dpi). TSP was extracted from
inﬁltrated leaves and analyzed by western blot to conﬁrm the
presence of eVLPs (Saunders et al., 2009). The same procedure
was followed for the expression of unmodiﬁed CPMV eVLPs, by
using pEAQ-HT-VP60 instead of pEAQ-HT-VP60-lipo.
For the large-scale puriﬁcation of CPMV-lipo, approximately
30 g of inﬁltrated leaves were homogenized in a blender with
four volumes (∼120 ml) of 0.1 M sodium phosphate buﬀer (pH
7.0) supplemented with 2% (w/v) polyvinylpolypyrrolidone and
complete EDTA-free protease inhibitor cocktail (Roche, Basel,
Switzerland). The extract was clariﬁed by ﬁltration through two
layers of Miracloth (Merck Millipore, Darmstadt, Germany)
and centrifugation (30,000 × g, 1 h, 4◦C). The supernatant
was fractionated by anionic exchange chromatography (DEAE
Sephadex A-50; GE Healthcare, Uppsala, Sweden), with a
sample-to-resin ratio of 4:1. The ﬂow-through fraction was
concentrated to 4 ml, centrifuged to remove insoluble particles
(10,000 × g, 10 min, 4◦C) and puriﬁed by size-exclusion
chromatography (HiPrep 16/60 Sephacryl S-500 HR; GE
Healthcare, Uppsala, Sweden) in 0.1 M sodium phosphate buﬀer
(pH 7.0) supplemented with 0.15 M NaCl at a ﬂow rate of
0.8 ml/min. Eluted fractions were analyzed by standard 12%
SDS-PAGE and silver staining. Fractions containing CPMV
eVLPs were pooled and concentrated using a 100 kDa cut-
oﬀ centrifugal ﬁlter (Merck Millipore, Darmstadt, Germany).
Puriﬁed particles were analyzed by 12% SDS-PAGE and silver
staining, and were quantiﬁed by measuring the absorbance at
280 nm.
Nanoparticle Characterization
Puriﬁed PVX particles were distributed on carbon/formvar
ﬁlm-coated 400 mesh copper grids (Electron Microscopy
Sciences, Hatﬁeld, PA, USA) and stained with 2% (w/v) uranyl
acetate for analysis using a JEM 1200 EXII (Jeol, Tokyo,
Japan) transmission electron microscope. The images were
acquired using an SIS Veleta charge-coupled device camera
(Olympus, Hamburg, Germany) at the Interdepartmental
Center of Electron Microscopy (University of Tuscia,
Italy).
Dynamic light scattering (DLS) was carried out using a
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). Puriﬁed
CPMV eVLPs (0.5 mg/ml) were centrifuged (10,000 × g, 10 min,
4◦C) before analysis to remove insoluble material. Measurements
were taken every 10 s and 12 measurements were averaged from
three runs at 25◦C.
ELISA
Maxisorp polystyrene plates (NUNC, Roskilde, Denmark) were
coated with the synthetic lipocalin peptide, PVX-lipo, CPMV-
lipo or the unmodiﬁed VNPs as controls each at a concentration
of 40 μg/ml in PBS. The plates were blocked for 1 h with 3%
bovine serum albumin (BSA) in PBS and then incubated with
diluted serum (1:200) from the patients and controls enrolled in
the study overnight at 4◦C. The plates were then washed once
with 1% Tween-20 in PBS and twice with PBS, before incubating
for 3 h at room temperature with an alkaline phosphatase-
conjugated anti-human IgG (Sigma–Aldrich, St Louis, MO,
USA) in diluting buﬀer, following manufacturer’s instructions.
After three washes, the enzymatic activity was measured using
p-nitrophenyl phosphate (Sigma–Aldrich, St Louis, MO, USA)
and a microplate absorbance reader (SunriseTM III, Tecan,
Männedorf, CH) set at 405 nm.
Optical density values higher than the mean of the control
group +3 SD were considered positive.
We used as internal positive control the serum of
one SjS patient which was previously used by Navone
et al. (2005) to assess the ELISA test with the synthetic
lipocalin peptide. Moreover, in the ELISA test with
synthetic peptide we used an uncoated well as corrector
factor. Similarly, the results for the VNPs displaying the
lipo peptide were corrected for the corresponding empty
scaﬀolds.
The sensitivity of the ELISA was calculated as the ratio of test-
positive SjS patients to the total number of patients aﬀected by
the disease and speciﬁcity as the ratio of test-negative individuals
to the total of SjS non-aﬀected individuals.
The stability of the ELISA was determined by coating the
plates with VNPs as above and then storing at 4◦C for 1, 15, 30,
or 60 days before testing.
Statistical Analysis
Quantitative data with a normal distribution were expressed
as means ± SD and were analyzed using Student’s t-test.
A multiple logistic regression analysis simultaneously controlling
for the titer of ANA, anti-ENA and anti-lipocalin antibodies,
as well as the presence or absence of other symptoms, was
used to evaluate the independent association between these
variables and pSjS. The speciﬁcity and sensitivity of the
ELISA was considered by testing its ability to distinguish
pSjS patients from healthy controls and patients with other
autoimmune diseases. All statistical calculations were carried
out using SPSS v21 with p < 0.05 considered statistically
signiﬁcant.
RESULTS
Segregation of Enrolled Patients and
Controls
We enrolled 91 patients aﬀected by pSjS, with amajority of female
enrollees (86 female, 5 male) reﬂecting the sex-based prevalence
of the disease. A control group of 120 subjects was also enrolled,
comprising 60 age/sex-matched healthy donors and 60 patients
aﬀected by other autoimmune disorders, i.e., 20 each with SSc,
RA, and SLE. The alternative autoimmune disease groups were
screened to exclude those showing evidence of sSjS. The SSc and
SLE patients showed ANA titers with a typical pattern speciﬁc for
each disease. The pSjS patients were assigned to groups according
to ANA titer and organ involvement, including 25 patients who
were ANA negative but showed histological evidence of salivary
gland involvement. Pulmonary and cardiac involvement, such as
vasculitis, arthralgias/arthritis andmyalgias, were also considered
as clinical aspects of interest. The clinical data are summarized in
Table 1.
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TABLE 1 | Clinical features and laboratory characterization of pSjS patients and controls, including healthy donors and patients with other autoimmune
diseases.
pSjS subjects
(n = 91)
Healthy controls
(n = 60)
SSc patients
(n = 20)
RA patients
(n = 20)
SLE patients
(n = 20)
Sex (female/male) 86/5 57/3 19/1 19/1 20/0
ANA titer 66/91 1/60 20/20 2/20 20/20
Presence SSA/SSB 27/91 0/60 1/20 0/20 3/20
Arthritis/arthralgias 79/91 0/60 1/20 20/20 11/20
Myalgias 58/91 0/60 4/20 0/20 8/20
Pulmonary involvement 3/91 0/60 9/20 2/20 0/20
CNS involvement 1/91 0/60 0/20 0/20 2/20
Vasculitis 3/91 0/60 0/20 0/20 0/20
Production of PVX and CPMV VNPs as
Scaffolds for the Lipocalin Peptide
The PVX-lipo VNPs were produced by introducing the lipocalin
synthetic peptide sequence into the vector pPVXSma (Lico et al.,
2006) to yield pPVXSma-lipo particles in which the peptide was
fused to the N-terminus of a truncated CP and displayed on
the particle surface. The peptide sequence was optimized for
N. benthamiana codon usage, and virusmovement was promoted
by adding a serine residue between the initiator codon and
the ﬁrst native residue (Betti et al., 2012). The production of
chimeric PVX particles depends on virus replication, so the
genetic stability of the virus genome was veriﬁed after several re-
infection cycles. The plants were infected using pPVXSma-lipo
plasmid DNA to initiate the ﬁrst cycle, followed thereafter by
infection using sap from symptomatic leaves obtained 12 days
after each round of infection. The chimeric CP gene remained
stable through several passages as demonstrated by RT-PCR
and sequencing (data not shown). The presence of PVX-
lipo and wild-type PVX was veriﬁed by western blot analysis
of infected leaf extracts (Figure 1A), where it is evident a
single band corresponding to the viral CP, with a molecular
weight shift in the PVX-lipo sample in comparison to wild-
type particles, corresponding to the lipo peptide fused to
the CP.
A larger number of plants were infected to obtain suﬃcient
leaf material for particle puriﬁcation (Uhde et al., 2005). We
achieved a yield of 0.11 mg PVX-lipo per gram fresh leaf weight
(FLW) and the purity of the particles was veriﬁed by SDS-
PAGE and silver staining (Figure 1B). N. benthamiana plants
were also infected with pPVX201 to obtain leaf material for the
production of unmodiﬁed PVX control particles (Figures 1A,B).
The yield was 0.62mg/g FLW. Transmission electron microscopy
conﬁrmed there were no morphological diﬀerences between
the chimeric PVX-lipo particles and the control particles
(Figures 1C,D).
The CPMV-lipo eVLPs were produced using the pEAQ-HT
system (Sainsbury et al., 2009). The VP60 CP precursor and the
24K protease were expressed on two separate pEAQ constructs
allowing the production of eVLPs structurally identical to wild-
type CPMV particles (Saunders et al., 2009). The sequence
encoding the target peptide was inserted into vector pEAQ-HT-
VP60, within the βB–βC loop of the small CP. N. benthamiana
leaves were agroinﬁltrated simultaneously with both vectors. Leaf
extracts were prepared 6 dpi for analysis by western blot using
anti-CPMV antibodies, revealing the presence of speciﬁc signals
corresponding to the large and small and a molecular weight
shift accounting for the modiﬁed small CP, thus conﬁrming the
insertion of the foreign peptide (Figure 2A).
A larger number of plants were inﬁltrated to obtain leaf
material for the puriﬁcation of unmodiﬁed CPMV and CPMV-
lipo eVLPs. Clariﬁed leaf protein extracts were processed by
anion exchange chromatography column to remove phenolic
compounds (Gecchele et al., 2014). The ﬂow through fraction
containing the eVLPs was concentrated and then puriﬁed
by size-exclusion chromatography. We achieved ﬁnal yields
of ∼0.04 mg/g and ∼0.05 mg/g FLW for the modiﬁed and
unmodiﬁed eVLPs, respectively. The purity of the eVLPs was
conﬁrmed by SDS-PAGE and silver staining (Figure 2B). DLS
conﬁrmed the correct assembly of the puriﬁed CPMV-lipo
eVLPs and revealed that the spherical particles had an outer
diameter of ∼28 nm as anticipated (Aljabali et al., 2010),
(Figure 2C).
Development of a VNP-based Direct
ELISA
The suitability of modiﬁed VNPs for the diagnosis of pSjS was
tested by comparing ELISAs based on the free synthetic peptide
to the diﬀerent VNP formats, and also by comparing modiﬁed
and unmodiﬁed VNPs, using sera from pSjS patients, healthy
controls and patients with other systemic autoimmune diseases
(Supplementary Figure S1). Preliminary comparative analysis of
the modiﬁed and unmodiﬁed VNPs allowed us to discard the
CPMV platform immediately because the unmodiﬁed particles
generated a stronger signal than the CPMV-lipo eVLPs and any
attempt to reduce this background failed (Supplementary Figure
S1B). All further experiments were therefore carried out using the
PVX platform.
We compared the PVX platform with the synthetic peptide
to evaluate the sensitivity and speciﬁcity of each ELISA. We
found that 90/91 patients with pSjS were correctly shown to
possess serum antibodies against lipocalin using the chimeric
PVX particles, whereas 79/91 were identiﬁed using the lipocalin
peptide alone. These results corresponded to a sensitivity of
86.8% for the synthetic peptide and 98.8% for the PVX-lipo
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FIGURE 1 | Analysis of PVX nanoparticles. (A) Western blot of N. benthamiana leaf TSP extracts, 24 μl per lane separated by SDS-PAGE and detected with an
alkaline phosphatase conjugated anti-PVX CP antibody. C = non-infected leaf extract, 1 = PVX-lipo leaf extract, and 2 = PVX control leaf extract. (B) Silver staining
of 750 ng purified particles separated by SDS-PAGE. 1 = PVX-lipo particles and 2 = PVX control particles. Arrows indicate the position of the 25 kDa molecular
marker. (C) Transmission electron micrographs of purified PVX-lipo particles and (D) PVX control particles. Scale bar = 100 nm.
particles (Table 2). Neither the synthetic peptide nor the PVX-
lipo particles were recognized by sera from healthy donors.
The proportion of positive results in the alternative systemic
autoimmune disease cohort was fewer than 10% of the SLE
patients, corresponding to the occurrence of sSjS, in agreement
with our previous data (Suresh et al., 2015), (Figure 3;
Supplementary Table S1). Autoimmune reactivity against the
lipo peptide therefore appears to be largely conﬁned to the
pSjS patient population. The speciﬁcity of quantitative analysis
was 90% for both the PVX-lipo and synthetic lipocalin peptide
ELISAs (Table 2).
We found that sera from the ANA-negative subgroup of SjS
patients with diagnostic salivary gland histology (25/91 patients)
reacted toward the PVX-lipo particles with a sensitivity of
98.7%, compared to 75% sensitivity in the peptide ELISA. There
was also a positive correlation between ANA titers and the
ELISA outcome. Patients with an ANA titer exceeding 1:160
produced strong signals in the ELISA (p = 0.023), although
there was no statistically signiﬁcant relationship between ANA
titers and the presence of anti Ro-SSA or anti La-SSB antibodies.
Moreover, there was a strong correlation between the ELISA
outcome and exocrine gland symptoms (p < 0.001) but not
with the involvement of other organs, e.g., pulmonary ﬁbrosis,
neurological pathology, or vasculitis. This may reﬂect the small
proportion of patients in our pSjS cohort presenting with these
symptoms.
Stability of the ELISA Test Over the Time
Finally, to demonstrate the stability and reproducibility of the
VNP-based ELISA, microtiter plates were coated with PVX-lipo,
stored at 4◦C and then used after 1, 15, 30, and 60 days to test the
sera from 18 SjS patients. The results of these tests did not change
regardless of the duration of storage, conﬁrming the stability of
the PVX-based ELISA format and the reproducibility of the assay
(Figure 4).
DISCUSSION
Primary SjS is a chronic autoimmune disorder characterized by
a spectrum of clinical features that are not always manifested in
each patient, and that may also be shared with other autoimmune
diseases, resulting in delayed and incorrect diagnoses. A key
diagnostic criterion is the presence of antinuclear antibodies, but
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FIGURE 2 | Analysis and characterization of CPMV eVLPs. (A) Western blot of N. benthamiana leaf TSP extracts, 11 μl per lane separated by SDS-PAGE and
detected with an alkaline phosphatase conjugated anti-CPMV CP antibody. C = non-infected leaf extract, 1 = CPMV-lipo leaf extract, and 2 = CPMV control leaf
extract. (B) Silver staining of 2 μg purified particles separated by SDS-PAGE. 1 = CPMV-lipo particles and 2 = CPMV control particles. Arrows indicate the position
of the 25 and 35 kDa molecular markers. (C) DLS analysis comparing purified CPMV-lipo (blue line) to unmodified CPMV (red line).
TABLE 2 | The sensitivity and specificity (expressed as a percentage) of
ELISAs based on the synthetic lipo peptide and PVX-lipo considering all
pSjS patients or the pSjS subgroup without ANA as a diagnostic
serological marker.
All pSjS patients ANA-negative pSjS
subgroup
Sensitivity Specificity Sensitivity Specificity
Synthetic lipo peptide 86.8 90 75 90
PVX-lipo 98.8 90 98.7 90
it is not unusual to encounter patients with pSjS-like symptoms
lacking this feature given that ANA titers are detected in only
60–85% of patients (Suresh et al., 2015).
In such cases, more invasive tests such as salivary gland and
labial biopsies must be used to conﬁrm the diagnosis but on the
basis of the negativity of ANA, the salivary gland biopsy may
sometimes be excluded, causing a delay or a real misdiagnosis.
Researchers have therefore focused on the development
of diagnostic tests for immunodominant autoantigens related
to pSjS. Antibodies against SP1, CA6, and PSP have been
investigated, but they appear to correlate primarily with
symptoms such as dry eyes and mouth and not with the
outcome of labial biopsies that provide a deﬁnitive pSjS diagnosis
(Suresh et al., 2015). The analysis of microRNAs targeting the
autoantigens Ro/SSA and La/SSB has suggested that miRNA
expression levels could be used to diagnose pSjS, but a
reproducible gene expression proﬁle in the disease has not been
conﬁrmed (Gourzi et al., 2015).
The screening of a random peptide library with IgG from
the sera of pSjS patients identiﬁed the immunodominant
peptide tear lipocalin, which can distinguish sera from pSjS
patients, healthy donors and individuals with other systemic
autoimmune disorders when used in an ELISA assay (Navone
et al., 2005). However, the sensitivity of diagnostic ELISA
test based on synthetic peptides is often reduced by the
interaction between the peptide and solid substrate, because
the functional epitope can be obstructed. We therefore
sought to determine whether the synthetic lipo peptide could
be replaced with VNPs displaying the peptide on a CP
scaﬀold.
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FIGURE 3 | PVX-lipo ELISA results using sera from different cohorts of
patients and controls, expressed in box-plot as mean absorbance
(optical density) ± SD. 1 = pSjS patients (n = 91), 2 = healthy donors
(n = 60), 3 = RA patients (n = 20), 4 = SSc patients (n = 20), and 5 = SLE
patients (n = 20).
Chimeric PVX particles were generated by fusing the
lipocalin peptide to the N-terminal region of the PVX
CP. The recombinant virus induced a systemic infection in
N. benthamiana, the model host for PVX, and the symptoms
were indistinguishable from those caused by the wild-type virus
(data not shown). Chimeric PVXparticles displaying the lipocalin
peptide (PVX-lipo) were genetically stable over three passages
of infection in plants (data not shown) and it was therefore
possible to propagate the virus and obtain a suﬃcient mass of
infected leaf tissue for the large-scale puriﬁcation of PVX-lipo
particles. The lipocalin peptide meets all the requirements for
the formation of stable chimeric PVX particles while preserving
virus movement through the plant (Lico et al., 2006), i.e., a
length of 12 amino acids, an isoelectric point of 8.75, and
the absence of tryptophan residues. The overall architecture of
the ﬂexuous chimeric particles was similar to that of wild-type
PVX.
Cowpea mosaic virus eVLPs displaying the lipocalin peptide
were produced by the proteolytic processing of CP precursors in
N. benthamiana plants as previously described (Saunders et al.,
2009). The peptide sequence did not interfere with the ability
of the modiﬁed CPs to assemble into CPMV-lipo eVLPs, which
accumulated to similar levels as the unmodiﬁed control eVLPs.
Both VNP systems were tested for their ability to recognize
anti-lipocalin autoantibodies present speciﬁcally in sera obtained
from pSjS patients. These preliminary tests revealed that the
CPMV-lipo eVLPs showed the same reactivity as their native
counterparts, whereas the PVX-lipo particles reacted speciﬁcally
to the pSjS patient sera and performed better than the synthetic
lipocalin peptide.
The diﬀerence in performance between the two VNP
platforms may reﬂect their distinct structures. PVX particles
comprise ∼1300 copies of identical CPs arranged in a helical
conﬁguration (Atabekov et al., 2007) whereas the icosahedral
CPMV particle comprises 60 copies each of the small and large
CP subunits, only the former of which is modiﬁed, resulting
in the display of 60 lipo peptides. The CPMV particles are
28 nm in diameter, compared to PVX with a diameter of
12 nm but a length of ∼550 nm. This means that PVX particles
display approximately 10 times as many peptides in the same
unit of surface area (PVX = 6.2 × 10−2 peptides/nm2 and
CPMV = 6.09 × 10−3 peptides/nm2). Furthermore, the rigid
icosahedral structure of CPMV and the position of the peptide
within the β-loop of the small CP subunit may constrain
its ability to be displayed whereas the peptides displayed on
the surface of PVX are fused to the N-terminus of the CP,
leading to a more ﬂexible and mobile structure maintaining
the linear conformation, which correctly promotes antibody
recognition.
The ELISA based on the PVX-lipo particles showed greater
sensitivity than the corresponding assay with synthetic peptide.
This may reﬂect the relatively ﬂat nature of the synthetic peptide
ELISA, with the synthetic peptide passively adsorbed to the
two-dimensional polystyrene surface of the microtiter plate,
compared to the three-dimensional nature of the VNPs, which
form a nanomolecular scaﬀold that increases the surface area of
the plate available for peptide display.
The PVX-based ELISA was also more reproducible than
the peptide ELISA (data not shown), reﬂecting the nature
of interaction between the binding reagent and the solid
substrate. Synthetic peptides are passively and non-covalently
adsorbed to the solid substrate, an interaction which is weak
due to the shortness of the peptide, and the structure of
the peptide is randomly oriented with respect to the surface
plane (Griesmann et al., 1991). In contrast, large and complex
multimeric proteins such as VNPs adsorb strongly to the
surface, and regardless of orientation, there remain plenty of
peptides projecting freely into solution to permit interactions
with serum antibodies. This increases the robustness and
reproducibility of the ELISA regardless of the chemical structure
of the peptide. However, synthetic peptide-based ELISA can
be improved by chemical modiﬁcations, such as biotinylation,
that may help in maintaining peptide conformation and
improve their adsorption to solid substrates (Jensen et al.,
2000).
The VNP-based ELISA was also remarkably stable. The plate
coated with PVX-lipo particles was stored at 4◦C for up to
2 months before use without any loss of sensitivity or speciﬁcity.
This again is likely to reﬂect the intrinsic characteristics of
the modiﬁed virus particles which have evolved to be resilient,
although the precise basis of their exceptional stability and
robustness remains unknown (Hammond and Hull, 1981;
Lukashina et al., 2012).
To our knowledge this is the ﬁrst report in which plant
VNPs have been used as a potentially diagnostic assay for
a human disease. Our results indicate that plant VNPs can
be used to display immunoreactive peptides for the ELISA-
based detection of serum autoantibodies and that VNP-based
assays are more sensitive than those based on synthetic
peptides, probably reﬂecting their much greater degree of
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FIGURE 4 | PVX-lipo ELISA results using sera from a subgroup of 18 pSjS patients at four time points to determine assay stability. (A) Each serum
sample was tested three times at each time point; average values of optical density are graphed on the y axis. Blue = 24 h, red = 15 days, green = 30 days, and
purple = 60 days. (B) Data set reporting the graphed data in (A) for each time point and each patient.
multivalency. Although many diﬀerent viruses have been used
for peptide display, plant viruses are particularly suitable for
the manufacture of diagnostic ELISAs, because they can be
produced eﬃciently and inexpensively at high titers in plants,
thus making plant suitable for the production of nanostructures
that are diﬃcult to express as active assemblies in microbial
cells.
CONCLUSION
Our data conﬁrm that the autoantigen lipocalin allows the
diagnosis of pSjS even in those patients lacking typical
disease markers such as antinuclear antibodies and antibodies
against Ro/SSA and La/SSB. We have demonstrated that
plants may be used to produce nanomaterials suitable for
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diagnostic assay development, suggesting that the concept we
have developed in the context of pSjS could be extended to other
diseases.
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FIGURE S1 | Comparison of results obtained in ELISA tests using
PVX and CPMV as scaffolds for lipo peptide. (A) PVX-lipo and PVX
OD results using sera from a sub-group of 20 SjS patients. Each serum
sample was tested three times for each system; average values of optical
density are graphed on the y-axis. (B) CPMV-lipo and CPMV OD results
using sera from the same sub-group of 20 SjS patients. Each serum
sample was tested three times for each system; average values of optical
density are graphed on the y-axis. Red line was used to represent VNPs
displaying the lipocalin peptide while the blue line represents empty viral
scaffolds.
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